When the matter came up before a bench of Justice P V Hardas and Justice Girish Kulkarni, the MCGM Commissioner sought time to file reply and the court granted two weeks' time.
On August 18, patients suffered adverse drug reactions after Caftriaxone and Cefotaxime injections were administered intravenously by doctors at the civic-run Bhabha Hospital, the PIL filed by activist Ketan Tirodkar alleged.
A fortnight ago, 18 children at a civic-run hospital in Bhiwandi had similar experience. Similarly, on August 22, at the Rajawadi Hospital in suburban Ghatkopar, patients complained of chills and abdominal pain after being injected with Cefotaxime and Ceftriaxone, the PIL further said.
The FDA officials visited Rajawadi Hospital and seized seven samples, the PIL claimed.
The inquiry panel would probe whether the drugs were stored improperly or in unsuitable storage condition, or whether syringes used were contaminated. The probe would also look into the quality of drugs and injection liquid as well as the method of administration of injections.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
